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clonal plasma cell burden is not as high and the plasma
cells are considered to be more indolent in AL amyloi-
dosis.12 However, as shown in MM this potent graft-ver-
sus-plasma-cell-dyscrasia-effect is also associated with
the occurrence of chronic GvHD. 
In summary, our report provides the rationale to fur-
ther investigate allo-SCT and post-transplant immuno-
therapeutic strategies in systemic AL amyloidosis. 
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In HPA 1a-immunized women the decrease in
anti-HPA 1a antibody level during pregnancy is
not associated with anti-idiotypic antibodies
A large screening and intervention study, aimed at
reducing morbidity and mortality associated with severe
anti-HPA 1a antibody induced neonatal alloimmune
thrombocytopenia (NAIT), has recently been carried out
in Norway.1 Recently, it was shown that the anti-HPA 1a
levels surprisingly decreased in 92 of 147 women who
had been pregnant previously and who carried an HPA 1a
positive fetus (P92 or more of 147=0.003).2 
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Figure 1. Description of hematologic and organ response in
Patient 1 (AL κ+). (A) FLC κ during treatment course. *2 cycles of
bortezomib were administered for re-induction before allo-SCT
and DLI. (B) Illustration of kidney response. Bars denote protein-
uria and the line the creatinine-clearance. A 50% reduction of pro-
teinuria was achieved since May 2008. cGvHD: chronic graft-ver-
sus-host-disease; CR: complete remission with conversion to
100% donor plasma cell chimerism; DLI: donor lymphocyte infu-
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The reason for decline in anti-HPA 1a antibodies dur-
ing pregnancy in multigravida is not known. One mech-
anism by which the antibody repertoire can be regulated
is via idiotypic networks. According to this concept an
HPA 1a-immunized woman may develop anti-idiotypic
antibodies (usually designated Ab2) which are antibodies
against antigenic determinants (idiotopes) on the vari-
able region of the anti-HPA 1a antibodies. These anti-
idiotypic antibodies may play an important immuno-reg-
ulatory role as they can blunt the initial immune
response (Ab1).3,4 We therefore examined whether the
observed decline in anti-HPA 1a antibody level in immu-
nized pregnant women was associated with a concurrent
increase in anti-idiotypic antibodies. The study was
approved by the Regional Committee for Medical
Research Ethics, North Norway (approval n. P-REK V
13/1995).
A total number of 829 samples of EDTA plasma were
collected from 157 HPA 1a-incompatible pregnancies
included in the screening and intervention study.1 As
controls we used 18 samples collected during pregnancy
in 4 non-HPA 1a-immunized pregnant women, and 28
samples from normal blood donors (11 males and 17
females). The labeling system for the control samples
was similar to the system used for the patients’ samples.
The coding (patients versus controls) was concealed until
all analyses were completed.
Anti-idiotypic activity was assessed as previously
described.5 Briefly, IgG was purified from 2 HPA 1a
immunized women (P1 and P2) and from one non-immu-
nized healthy control (C). F(ab’)2 fragments (from P1, P2
and C) prepared by pepsin digestion were used as coat-
ing proteins in an enzyme-linked immunosorbent assay
(ELISA) for detection of anti-idiotypic antibodies (Ab2) in
plasma from patients and controls. 
On each ELISA plate four different dilutions of
immunoglobulin (100, 50, 25 and 12.5 µg/mL; Gamunex,
Talecris Biotherapeutics, Mississauga, ON, Canada) as
well as plasma samples from 2 of 4 healthy individuals
were included as controls. The results from these healthy
individuals were not analyzed in a blinded fashion, and
hence they were not included in the statistical analysis.
All samples from individual pregnant women were ana-
lyzed on one ELISA plate.
There was no significant difference in anti-idiotypic
reactivity between samples from HPA 1a-immunized
women and controls. There was no significant difference
in the dispersion of anti-idiotypic reactivity between the
study objects and the controls and no obvious difference
in the frequency distribution pattern of anti-idiotypic
reactivity between study objects and controls (Figure 1),
indicating that the observed reactivity was not directed
against the anti-HPA 1a specific F(ab’)2 fragments. When
the analysis was restricted to those women in whom
there was a decrease in anti-HPA 1a level during preg-
nancy, we again could not find a concurrent increase in
anti-idiotypic reactivity. 
Our results contrast with a previous report suggesting
that anti-idiotypic networks play a pivotal role in regula-
tion of anti-HLA antibody levels. Atlas et al. showed that
55 of 82 multitransfused HLA immunized patients with
decreasing anti-HLA antibody levels over time, had con-
currently increasing levels of anti-idiotypic antibodies in
their sera.6 Anti-idiotypic antibodies could not be found
in sera from patients with persistently high anti-HLA
antibody levels.6 In addition, more than one third of the
anti-idiotypic antibodies inhibited the binding of the anti-
HLA antibodies to platelets, indicating that they were
specific for the paratopes of the anti-HLA andibodies.6
One possible explanation for the discrepancy between
our results and those reported by Atlas et al. is that
alloimmunization in NAIT is caused by a point mutation
where a single nucleotide substitution results in one
amino acid replacement at position 33 in GPIIIa (from
proline in HPA 1b to leucine in HPA 1a), whereas in
HLA-alloimmunization the antigenic diversity between
different HLA molecules is much larger. Consequently
the antibody repertoire of anti-HLA antibodies is consid-
erably larger than that of anti-HPA 1a antibodies and per-
haps the latter antibodies (Ab1) cannot effectively gener-
ate the production of anti-idiotypic antibodies (Ab2). 
In conclusion, it is unlikely that idiotypic regulation of
anti-HPA 1a antibodies occurs during pregnancy in HPA
1a-immunized women.
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Figure 1. The frequency distribution of patient and control samples. The anti-idiotypic reactivities (OD at 405 nm) against F(ab’)2 frag-
ments from the two HPA 1a-immunized women (P1 and P2) and the healthy control (C) are shown.
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Slow responses to standard dose rituximab in
immune thrombocytopenic purpura 
We read with interest the article by Zaja et al. in which
the results of a prospective multicenter Phase II study to
assess the response rates of lower dose rituximab in
adults with chronic immune thrombocytopenic purpura
(ITP) were reported.1 In this single arm study 28 ITP
patients received rituximab (100 mg/m2) weekly for four
weeks. An overall response (platelet count >50×106/L)
and complete response (platelet count >100×109/L) was
achieved in 21/28 (75%) and 12/28 (43%) of patients,
respectively. Interestingly the time to treatment
response with lower dose rituximab was longer than in
published studies with standard dose (375mg/m2 week-
ly for four weeks).2-4 The median time to a complete
response was 44 days with a range of 7-90 days.
In a recent prospective Phase II study which assessed
the efficacy of standard dose rituximab in chronic adult
ITP patients, most patients who responded to rituximab
did so early and none of the patients who failed to reach
a platelet count of 50×109//L in two weeks achieved a
good response at one year.2
In our center we have treated 11 patients (6 female
and 5 male, mean age 50) with refractory chronic ITP
with standard dose rituximab (375 mg/m2 weekly for
four weeks) with similar response rates (6 patients
reached a platelet count of >50×109/L, including 3
>100×109/L at six months) but we have noted that
delayed responses to standard dose rituximab also occur
(Figure 1). The best responses were seen in 2 female
patients, aged 32 and 26 years, with baseline platelet
counts of 4 and 25×109/L. Their platelet counts at one
month were 87 and 84×109/L and at six months were
521 and 230×109/L, respectively without any further
treatment. In fact in our experience, at one month, no
patient had platelets > 100×109/L (Figure 1). In a sys-
temic review, complete responses usually occurred 3-8
weeks after the first infusion of rituximab.5 However,
our data show that delayed responses to standard dose
rituximab can occur. These responses are unlikely to
reflect spontaneous remission as this rarely occurs in
adult chronic ITP.6
Splenectomy has been considered standard second-
line therapy for ITP.7 The response rate is about 65%
but it is associated with a mortality of 0.2-1% and mor-
bidity of 9.6-12.9% depending on the age of the patient
and technique used.8 There is accumulating evidence
that rituximab can be a safe and effective way to defer
splenectomy particularly in younger patients.9 A lower
dose rituximab regimen would result in considerable
cost savings compared to a standard dose regimen and
may be associated with less transfusion related reac-
tions. While delayed responses may occur in the lower
dose regimen they may also occur with standard dose
rituximab. Since maximal response to both dosing regi-
mens may be delayed, a decision regarding splenectomy
should not be made until at least six months after ritux-
imab therapy.
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Figure 1. Response of chronic ITP patients over time, following
first rituximab infusion. Complete response (CR), platelet count
>100×109/L partial response (PR), platelet count 50-100×109/L.
No response (NR). The arrows and overlying numbers represent
patients changing response. Patients who required alternative
treatment were classified as having no response.
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